|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Micrus Endovascular Corporation (NASDAQ: MEND), a developer of implantable and disposable medical devices used in the treatment of cerebral vascular diseases. |
|---|---|
| Transferring Party | VasCon LLC Micrus Design Technology, Inc., a developer of advanced access and diagnostic and steerable catheter systems |
| Sector | Medical Devices |
| Date | December 1, 2006 |
| Analysis Expands Micrus' core competencies; part of its strategy to become a full-line endovascular company, addressing the neurointerventional market. VasCon's existing cardiovascular products will to be sold through non-Micrus distribution channels. Deal price -- $5m plus earnout. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |